SCHEMBL25552247

SCHEMBL25552247

CON(C)C(=O)c1cc(I)cs1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 1/20 0.43
DYRK1A Q13627 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
ICAM1 P05362 1/20 0.36
SELE P16581 1/20 0.36
HSD17B1 P14061 2/20 0.35
HSD17B2 P37059 2/20 0.35
MLYCD O95822 1/20 0.33
DAO P14920 1/20 0.32
TRPM8 Q7Z2W7 2/20 0.32
SLC6A3 Q01959 1/20 0.31
HPGD P15428 1/20 0.31
HTT P42858 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
MAPT P10636 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24426051 0.81 CES2 (0.52) CLK1DYRK1ADYRK1BICAM1SELE
SCHEMBL22870260 0.81 DAO (0.53) CLK1DYRK1ADYRK1BICAM1SELE
SCHEMBL25561361 0.79 CLK1 (0.43) CLK1DYRK1ADYRK1BICAM1SELE
SCHEMBL21963072 0.79 CLK1 (0.43) CLK1DYRK1ADYRK1BICAM1SELE
SCHEMBL25561359 0.77 HPGD (0.45) CLK1DYRK1ADYRK1BICAM1SELE
SCHEMBL25552245 0.76 MLYCD (0.43) CLK1DYRK1ADYRK1BICAM1SELE
SCHEMBL4255563 0.74 CTPS1 (0.42) DAOHPGDMAPTNPSR1
SCHEMBL2510458 0.70 CLK1 (0.41) CLK1DYRK1ADYRK1BICAM1SELE
SCHEMBL14594121 0.70 CLK1 (0.54) CLK1DYRK1ADYRK1BICAM1SELE
SCHEMBL14594132 0.69 CLK1 (0.50) CLK1DYRK1ADYRK1BHSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12565490-B2 Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2026-03-03 US disclosed
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-05-25 US disclosed
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-05-25 US disclosed
EP-4110765-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE Board of Regents, The University of Texas System (US) 2023-01-04 EP disclosed
CN-115515940-A Inhibitors of receptor interacting protein kinase I for the treatment of disease 德州大学系统董事会 2022-12-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE RIPK1, RIPK2, RIPK4 CLK1 667/4885DYRK1A 1635/4885DYRK1B 1793/4885
US-12565490-B2 Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease RIPK1, RIPK4, RIPK2 CLK1 389/4885DYRK1A 847/4885DYRK1B 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.